Intratumoral Therapy to Make a “Cold” Tumor “Hot”: The Jury Is Still Out

Tilsotolimod, an oligodeoxynucleotide TLR9 agonist, administered intratumorally, has been clinically evaluated. This compound has demonstrated the ability to induce changes within the tumor microenvironment, to convert noninflamed cold tumors into inflamed hot tumors, with the hope that these tumors will be more responsive to immune checkpoint blockade.

See related article by Babiker et al., p. 5079